Sanofi warns of haemophilia risk with clopidogrel

By News team

Patients taking clopidogrel may be at risk of acquired haemophilia, according to manufacturer Sanofi.

In a to healthcare professionals, Sanofi warns that there has been a small number of cases of acquired haemophilia in individuals with no previous history of abnormal haemostasis reported since the product’s launch.

Mark Toms, medical director at Sanofi UK/Ireland, said: “Eleven case reports of acquired haemophilia A and one case report of acquired haemophilia B associated with clopidogrel treatment have been transmitted to Sanofi. Time to onset ranged from a few days to four months after starting clopidogrel treatment. Two cases were life-threatening and none had a fatal outcome.”

Product information is being updated with information on this risk but, according to Dr Toms, the benefit versus risk balance of clopidogrel “is considered unchanged in the approved therapeutic indications”.

Acquired haemophilia should be considered in cases of isolated activated partial thromboplastin time prolongation with or without bleeding. Patients with a confirmed diagnosis of acquired haemophilia should be treated by specialists and clopidogrel discontinued.

Citation: The Salvadore DOI: 10.1211/PJ.2013.11125684

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

RPS publications

Pharmaceutical Press is the publishing division of the SalvaDore, and is a leading provider of authoritative pharmaceutical information used throughout the world.

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete

Supplementary images

  • Blood clot (Sebastian Kaulitzki/

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.